These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29308691)

  • 21. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carfilzomib: a rare cause of posterior reversible encephalopathy syndrome.
    Katz-Agranov N; Padilla J; Scoon J; Cherian SV
    Ann Hematol; 2016 Oct; 95(11):1923-4. PubMed ID: 27477479
    [No Abstract]   [Full Text] [Related]  

  • 23. Infection risk with carfilzomib in multiple myeloma: a systematic review and meta-analysis of randomised controlled trials.
    Wongsaengsak S; Kopel J; Behera TR; Chakraborty R; Ball S
    Br J Haematol; 2020 Jul; 190(2):e95-e97. PubMed ID: 32400886
    [No Abstract]   [Full Text] [Related]  

  • 24. Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
    Bilotti E
    Clin J Oncol Nurs; 2013 Apr; 17(2):E35-44. PubMed ID: 23538263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
    Rosenthal A; Luthi J; Belohlavek M; Kortüm KM; Mookadam F; Mayo A; Fonseca R; Bergsagel PL; Reeder CB; Mikhael JR; Stewart AK
    Blood Cancer J; 2016 Jan; 6(1):e384. PubMed ID: 26771810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carfilzomib-induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study.
    Kozlowski P; Kameran Behnam K; Uggla B; Åström M
    Eur J Haematol; 2020 Jun; 104(6):588-593. PubMed ID: 32115785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
    Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
    Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
    Stewart AK
    Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing adverse events of multiple myeloma and anti-multiple myeloma treatment: a perspective on carfilzomib.
    Siegel DS
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():2-3. PubMed ID: 25184229
    [No Abstract]   [Full Text] [Related]  

  • 31. Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations.
    Chavda SJ; Pocock R; Cheesman S; Lee KM; Dowling E; Marks DJB; Kyriakou C; Lee L; Sive J; Wechalekar A; Rabin N; Yong K; Popat R
    Br J Haematol; 2020 Sep; 190(5):e312-e316. PubMed ID: 32535901
    [No Abstract]   [Full Text] [Related]  

  • 32. Carfilzomib (Kyprolis°) in multiple myeloma.
    Prescrire Int; 2017 May; 26(182):120. PubMed ID: 30730668
    [No Abstract]   [Full Text] [Related]  

  • 33. Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database.
    Fakhri B; Fiala MA; Shah N; Vij R; Wildes TM
    Cancer; 2020 Feb; 126(4):808-813. PubMed ID: 31721140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
    Moreau P
    Expert Rev Hematol; 2014 Apr; 7(2):265-90. PubMed ID: 24521249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteasome inhibitors for the treatment of multiple myeloma.
    Scalzulli E; Grammatico S; Vozella F; Petrucci MT
    Expert Opin Pharmacother; 2018 Mar; 19(4):375-386. PubMed ID: 29478351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience.
    Uysal A; Akad Soyer N; Özkan M; Şahin F; Vural F; Töbü M; Tombuloğlu M; Saydam G
    Turk J Med Sci; 2018 Feb; 48(1):80-83. PubMed ID: 29479960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management.
    Wu P; Oren O; Gertz MA; Yang EH
    Curr Oncol Rep; 2020 Jun; 22(7):66. PubMed ID: 32514632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
    Danhof S; Schreder M; Rasche L; Strifler S; Einsele H; Knop S
    Eur J Haematol; 2016 Jul; 97(1):25-32. PubMed ID: 26331915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation.
    Kint NG; Heylen E; Pepe D; De Keersmaecker K; Verfaillie CM; Delforge M
    Leukemia; 2020 Feb; 34(2):651-655. PubMed ID: 31467428
    [No Abstract]   [Full Text] [Related]  

  • 40. Arterial Hypertension and Multiple Myeloma: Physiopathology and Cardiovascular Risk and 'Practical' Indications in Patients Receiving Carfilzomib.
    Milan A; Bruno G; Maffei I; Iannaccone A; Ravera A; Schiavone D; Veglio F
    Curr Hypertens Rev; 2019; 15(1):47-53. PubMed ID: 29886833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.